A new study presented at the 2024 San Antonio Breast Cancer Symposium suggests:
⤷ Giving PARP Inhibitor (Olaparib) for one year after standard cancer treatment led to benefits in BRCA-mutation breast cancers.
What was seen?
- Olaparib lowered the risk of breast cancer recurrence.
- Fewer patients who received olaparib (compared to placebo) died during follow-up
These findings bring up the possibility of considering using PARP inhibitors in BRCA carriers:
- in lower risk breast cancers
- for cancer interception (drug given intermittently to eliminate cells that have started to transform toward becoming cancerous)
To learn more, read the full article at: https://www.healio.com/news/hematology-oncology/20241211/olaparib-confers-durable-benefit-in-brcamutated-breast-cancer